Abeona Therapeutics (ABEO) announced that the Centers for Medicare and Medicaid Services has established a permanent Healthcare Common Procedure Coding System J-code for ZEVASKYN gene-modified cellular sheets, the Company’s autologous gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. The new J-code for ZEVASKYN, J3389 becomes effective on January 1, 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development
- Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA
- Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success